AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 278: E684-E691, 2000;
0193-1849/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mulder, H.
Right arrow Articles by Ahrén, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulder, H.
Right arrow Articles by Ahrén, B.
Vol. 278, Issue 4, E684-E691, April 2000

Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes

Hindrik Mulder1,2, Samuel Gebre-Medhin3,4, Christer Betsholtz4, Frank Sundler2, and Bo Ahrén5

1 Section for Molecular Signaling, Department of Cell and Molecular Biology, Lund University, SE-221 00 Lund; 2 Section for Neuroendocrine Cell Biology, Department of Physiological Sciences, Lund University, SE-221 85 Lund; 3 Section for Molecular and Cellular Physiology, Department of Physiological Sciences, Lund University, SE-223 62 Lund; 5 Dept. of Medicine at Malmö University Hospital, Lund University, SE-205 02 Malmo; and 4 Dept. of Medical Biochemistry, Göteborg University, SE-405 30 Goteborg, Sweden

To examine whether islet amyloid polypeptide (IAPP), other than through amyloid formation, may be of importance in diabetes pathogenesis, IAPP-deficient mice (IAPP-/-) were challenged with alloxan (day 0). Diabetes in IAPP-/- mice was more severe at day 35, indicated by greater weight loss; glucose levels were higher in alloxan-treated IAPP-/- mice, whereas insulin levels were lower, indicating a greater impairment of islet function. Accordingly, glucose levels upon intravenous glucose challenges at days 7 and 35 were consistently higher in alloxan-treated IAPP-/- mice. At day 35, insulin mRNA expression, but not beta -cell mass, was lower in untreated IAPP-/- mice. Yet, upon alloxan administration, beta -cell mass and numbers of beta -cell-containing islets were significantly more reduced in IAPP-/- mice. Furthermore, they displayed exaggerated beta -cell dysfunction, because in their remaining beta -cells, insulin mRNA expression was significantly more impaired and the localization of glucose transporter-2 was perturbed. Thus the lack of IAPP has allowed exaggerated beta -cell cytotoxic actions of alloxan, suggesting that there may be beneficial features of IAPP actions in situations of beta -cell damage.

gene knockout; beta -cell mass; insulin messenger ribonucleic acid; glucose transporter-2; glucose tolerance


This article has been cited by other articles:


Home page
 J. Histochem. Cytochem.Home page
K. Iki and P. M. Pour
Distribution of Pancreatic Endocrine Cells Including IAPP-expressing Cells in Non-diabetic and Type 2 Diabetic Cases
J. Histochem. Cytochem., February 1, 2007; 55(2): 111 - 118.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online